Safety and efficacy of pregabalin in adolescents with fibromyalgia

Fibromyalgia is a condition that affects millions of individuals in the United States. The characteristic findings include chronic pain and tenderness in the joints, muscles, tendons and other soft tissues. Patients may also experience headaches, depression, anxiety and sleep disturbances. This study is evaluating the safety and efficacy of pregabalin to treat adolescent patients with fibromyalgia

Medication Under Study:

Full study title:
A 15-week, randomized, double blind, parallel-group, placebo-controlled, flexible-dose, safety and efficacy study of pregabalin in adolescents (12-16 years old) with fibromyalgia

IRB Study ID:

Who may qualify:

Adolescent patients (12-16 years) with fibromyalgia

Who does not qualify:

Patients under 12 years old or those with certain medical conditions

If you are interested in this study or have questions about your child's eligibility, please contact:

Rebecca D. Considine Research Institute, 330-543-5012

For urgent patient care matters involving a current study patient, please call: 330-920-5774

Lead Principal Investigator:

Mary Bratovich Toth, MD
Director, Pediatric Rheumatology
Medical Staff, President

Bookmark and Share

iGrow iGrow
Sign up for our parent enewsletter
    Contact Us



    find a location
    Find a location Type the first 3-5 letters of a specialty, service or location:
    Or, view: a map, a list of all locations, locations by city or locations near me.
    find a doctor
    Find a doctor Type the first 3-5 letters of the name, location or specialty:
    Or, view a list of all doctors by name, location and specialty.